(19)
(11) EP 3 488 443 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
29.09.2021 Bulletin 2021/39

(45) Mention of the grant of the patent:
18.08.2021 Bulletin 2021/33

(21) Application number: 17743311.7

(22) Date of filing: 19.07.2017
(51) International Patent Classification (IPC): 
C12N 15/10(2006.01)
(52) Cooperative Patent Classification (CPC):
G16B 20/10; C12N 15/10; C12Q 2600/106; C12Q 1/68; C12Q 2600/156; Y02A 90/10; G16H 20/10; C12Q 1/6886
(86) International application number:
PCT/EP2017/068226
(87) International publication number:
WO 2018/015433 (25.01.2018 Gazette 2018/04)

(54)

SELECTING NEOEPITOPES AS DISEASE-SPECIFIC TARGETS FOR THERAPY WITH ENHANCED EFFICACY

AUSWAHL VON NEOEPITOPEN ALS KRANKHEITSSPEZIFISCHE ZIELE FÜR EINE THERAPIE MIT ERHÖHTER WIRKSAMKEIT

SÉLECTION DE NÉOÉPITOPES EN TANT QUE CIBLES SPÉCIFIQUES DE MALADIE POUR UN TRAITEMENT PRÉSENTANT UNE EFFICACITÉ ACCRUE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 20.07.2016 WO PCT/EP2016/067348

(43) Date of publication of application:
29.05.2019 Bulletin 2019/22

(60) Divisional application:
21178672.8

(73) Proprietor: BioNTech SE
55131 Mainz (DE)

(72) Inventors:
  • TADMOR, Arbel D.
    55294 Bodenheim (DE)
  • SAHIN, Ugur
    55116 Mainz (DE)

(74) Representative: Schnappauf, Georg et al
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)


(56) References cited: : 
WO-A1-2013/120509
WO-A2-2012/159754
WO-A2-2011/143656
US-A1- 2015 331 992
   
  • TUERECI OEZLEM ET AL: "Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines", CLINICAL CANCER RESEARCH, vol. 22, no. 8, April 2016 (2016-04), pages 1885-1896, XP055300469, ISSN: 1078-0432
  • CASTLE JOHN C ET AL: "Mutated tumor alleles are expressed according to their DNA frequency", SCIENTIFIC REPORTS, vol. 4, April 2014 (2014-04), pages 1-6, XP002774681, ISSN: 2045-2322
  • SCOTT L CARTER ET AL: "Absolute quantification of somatic DNA alterations in human cancer", NATURE BIOTECHNOLOGY, vol. 30, no. 5, 1 January 2012 (2012-01-01), pages 413-421, XP055042894, ISSN: 1087-0156, DOI: 10.1038/nbt.2203
  • MYHRE SIMEN ET AL: "Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins", MOLECULAR ONCOLOGY, vol. 7, no. 3, June 2013 (2013-06), pages 704-718, XP002777340, ISSN: 1574-7891
  • GUNNARSSON CECILIA ET AL: "Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer", BREAST CANCER RESEARCH AND TREATMENT, vol. 108, no. 1, March 2008 (2008-03), pages 35-41, XP002777341, ISSN: 0167-6806
  • WANG TIM ET AL: "Identification and characterization of essential genes in the human genome", HHS Public Access Author Manuscript , November 2015 (2015-11), pages 1-13, XP002777395, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC4662922/ [retrieved on 2018-01-18]
  • CHIARI RITA ET AL: "Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene", CANCER RESEARCH, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5785-5792, XP055111371, ISSN: 0008-5472
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).